

# Crown Agents Ukraine - General Procurement Notice – addendum 2

## Requirements for Programme 8 – Medicines for adults with primary immune deficiency diseases

International non-proprietary name	Form of presentation	Dosage	Estimated Demand, 100%	Estimated Quantity under the Assets Allocated
Human normal immunoglobulin for intravenous administration	vial	50 ml, 5% (50 mg/ml)	4	4
Human normal immunoglobulin for intravenous administration	—“—	100 ml, 5% (50 mg/ml)	697	585
Human normal immunoglobulin for intravenous administration	—“—	50 ml, 10% (100 mg/ml)	3,288	2,758
Human normal immunoglobulin for intravenous administration	—“—	100 ml, 10% (100 mg/ml)	894	751
Human normal immunoglobulin for subcutaneous administration	—“—	10 ml, 15–20% (150–200 mg/ml)	580	488
Human normal immunoglobulin for subcutaneous administration	—“—	20 ml, 15–20% (150–200 mg/ml)	2,738	2,296
C1 Esterase Inhibitor (Human)	vial, lyophilizate for solution for intravenous injections	1 IU	1,137,563	954,585
Anakinra	pre-filled syringe	100 mg/0.67 ml	1,095	918